Germany's Bayer will continue its expansion into the U.S. despite its announcement that its promising blood thinner candidate failed to demonstrate superiority over a competing medicine.
Bristol Myers Squibb (BMY.N) CEO Christopher Boerner said on Monday the drugmaker expects to add 16 new products to its portfolio by the end of the decade.
The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.
Boston Scientific Corp. agreed to pay $71 a share in cash for medical technology firm Axonics Inc., a maker of devices to treat urinary and bowel dysfunction.
Merck & Co. has agreed to acquire cancer drugmaker Harpoon Therapeutics Inc. for $680 million as it seeks to solidify its leadership position in the profitable oncology space.